Media ReleasesLBT Innovations

View All LBT Innovations News

AstraZeneca Partners with LBT for APAS Pharma Development

Adelaide, Australia, 09 January 2023: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, is pleased to announce the Company has been engaged by AstraZeneca for the full product development for its APAS® Pharma product.

Key Points:
-- AstraZeneca engages LBT following successful APAS® Pharma proof-of-concept
-- Supports LBT’s goal to automate pharmaceutical microbial quality control testing globally
-- Funded development project - ~AUD$1m to be received based on achieving technical milestones
-- >350 million microbial quality control tests performed annually: Potential $10bn market opportunity
-- Utilises existing APAS® Independence hardware, developing new APAS® Pharma software

LBT has been engaged by AstraZeneca, a global biopharmaceutical company, to undertake a full product development project for the Company’s new APAS® Pharma analysis module (artificial intelligence software) to be used on the APAS® Independence instrument. The APAS® Pharma analysis module will be developed to identify microbial growth on settle plates used in sterility monitoring during drug manufacturing.

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?